Fatty Liver Epidemic Threatens Two Billion People – Experts Warn of Silent Liver Damage and Urgent Need for Early Action

Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as non-alcoholic fatty liver disease (NAFLD), is projected to affect nearly 2 billion people worldwide by 2050, according to a new study published in The Lancet Gastroenterology & Hepatology journal. The findings, based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD), indicate that current cases have surged to 1.3 billion globally, marking a 143% increase since 1990. This sharp rise underscores MASLD as one of the most prevalent and rapidly growing liver conditions worldwide.

The study reveals that in 1990, approximately 500 million people were living with MASLD. By 2023, that number had climbed to 1.3 billion, and projections show it will reach 1.8 billion by 2050—a 42% increase from current levels. The global prevalence rate rose to 14,429 cases per 100,000 people in 2023, representing a 29% increase from 1990. These trends are driven by a combination of population growth, rising obesity rates, and increasing levels of high blood sugar, which researchers identified as the leading contributor to MASLD-related health problems.

High blood sugar was identified as the primary driver of MASLD-related health complications, followed by high body mass index (BMI) and smoking. The condition is more prevalent in men than women and shows the highest rates among adults aged 80 to 84. However, the largest number of affected individuals falls within younger age groups—men aged 35 to 39 and women aged 55 to 59—highlighting the disease’s broad impact across demographics.

MASLD is closely linked to metabolic syndrome and frequently co-occurs with obesity, type 2 diabetes, and sedentary lifestyles. In the United States, an estimated quarter of the population has NAFLD, and up to 70% of people with type 2 diabetes also have the condition, according to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Although often asymptomatic in early stages, MASLD can progress to nonalcoholic steatohepatitis (NASH), involving liver inflammation and fibrosis that may lead to cirrhosis, liver cancer, or liver failure requiring transplantation over time.

Currently, no therapies are approved by the U.S. Food and Drug Administration (FDA) specifically for NAFLD or NASH. The standard of care remains lifestyle modification, particularly weight loss through diet and exercise, which many patients find difficult to sustain, and achieve. Diagnosis remains challenging, as it often relies on invasive liver biopsy, underscoring the need for noninvasive diagnostic tools and improved screening strategies.

Researchers emphasize that MASLD is not merely a liver condition but part of a broader metabolic crisis tied to rising rates of lifestyle-related disorders. The study notes that the burden is shifting toward densely populated and developing regions, including South Asia, particularly India, where urbanization and dietary changes are accelerating risk factors. These geographical trends align with global patterns where non-communicable diseases are surpassing infectious diseases as primary public health challenges.

The study’s authors caution that without targeted public health interventions addressing obesity, diabetes, and metabolic health, the projected rise in MASLD cases will strain healthcare systems worldwide. They call for increased investment in prevention, early detection, and accessible treatment options, especially in underserved populations where the disease burden is growing fastest. Continued surveillance through initiatives like the GBD study will be critical to tracking progress and informing policy responses in the coming decades.